SG11201503051QA - Formulations of pyrimidinedione derivative compounds - Google Patents

Formulations of pyrimidinedione derivative compounds

Info

Publication number
SG11201503051QA
SG11201503051QA SG11201503051QA SG11201503051QA SG11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA SG 11201503051Q A SG11201503051Q A SG 11201503051QA
Authority
SG
Singapore
Prior art keywords
formulations
derivative compounds
pyrimidinedione derivative
pyrimidinedione
compounds
Prior art date
Application number
SG11201503051QA
Other languages
English (en)
Inventor
Yanxia Li
Ping Gao
Yi Shi
Hao Hou
Michael Mackaplow
Kelley A Meadows
Geoff G Zhang
Yi Gao
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201503051QA publication Critical patent/SG11201503051QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201503051QA 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds SG11201503051QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261715766P 2012-10-18 2012-10-18
PCT/US2013/065760 WO2014063101A1 (fr) 2012-10-18 2013-10-18 Formulations de composés dérivés de pyrimidinedione

Publications (1)

Publication Number Publication Date
SG11201503051QA true SG11201503051QA (en) 2015-05-28

Family

ID=49554481

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503051QA SG11201503051QA (en) 2012-10-18 2013-10-18 Formulations of pyrimidinedione derivative compounds

Country Status (11)

Country Link
US (2) US9629841B2 (fr)
EP (1) EP2908808A1 (fr)
JP (2) JP6266635B2 (fr)
CN (2) CN104853752B (fr)
AU (1) AU2013330993B2 (fr)
BR (1) BR112015008927A2 (fr)
CA (1) CA2888883A1 (fr)
EA (2) EA028481B1 (fr)
MX (1) MX2015004973A (fr)
SG (1) SG11201503051QA (fr)
WO (1) WO2014063101A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
CN115605186A (zh) * 2020-03-05 2023-01-13 奥瑞基尼探索技术有限公司（In） 激酶抑制剂的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
DE69934582T2 (de) 1998-06-11 2007-10-04 Pharmacia & Upjohn Co. Llc, Kalamazoo Delavirdin tablettenformulierung
EP1738749A1 (fr) 1999-12-23 2007-01-03 Pfizer Products Inc. Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorées
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
CA2590675A1 (fr) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Formulations renfermant des nanoparticules de tacrolimus
WO2007044574A2 (fr) * 2005-10-06 2007-04-19 Transtech Pharma, Inc. Compositions pharmaceutiques, leurs procedes de preparation, et procedes de traitement
CN102746240B (zh) * 2007-09-17 2017-10-03 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CA2976793A1 (fr) * 2007-09-17 2009-03-26 Abbvie Ireland Unlimited Company Derive d'uracile ou de thymine pour le traitement de l'hepatite c
US20100166861A1 (en) * 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
AU2011223895A1 (en) 2010-03-01 2012-09-13 Concert Pharmaceuticals Inc. Fluorouracil derivatives
CH707030B1 (de) * 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV

Also Published As

Publication number Publication date
CA2888883A1 (fr) 2014-04-24
EA201791354A3 (ru) 2018-03-30
CN104853752B (zh) 2018-10-23
MX2015004973A (es) 2015-07-17
WO2014063101A1 (fr) 2014-04-24
AU2013330993B2 (en) 2018-03-01
US9629841B2 (en) 2017-04-25
JP6266635B2 (ja) 2018-01-24
EA028481B1 (ru) 2017-11-30
EP2908808A1 (fr) 2015-08-26
BR112015008927A2 (pt) 2017-07-04
CN104853752A (zh) 2015-08-19
CN109260207A (zh) 2019-01-25
JP2018065858A (ja) 2018-04-26
US20170181973A1 (en) 2017-06-29
EA201791354A2 (ru) 2017-11-30
EA032913B1 (ru) 2019-08-30
US10201542B2 (en) 2019-02-12
AU2013330993A1 (en) 2015-05-07
EA201590752A1 (ru) 2016-02-29
US20140113921A1 (en) 2014-04-24
JP2015534985A (ja) 2015-12-07

Similar Documents

Publication Publication Date Title
IL277652A (en) Stable aqueous formulations of adlimumab
HK1212701A1 (zh) 恩雜魯胺製劑
HK1213174A1 (zh) 穩定的含水依那西普製劑
EP2814487A4 (fr) Formulations de bendamustine
HK1210914A1 (en) Formulations of clomazone
FI2827862T3 (fi) Bendamustiinin formulaatioita
HK1207081A1 (en) Crystalline forms of dihydropyrimidine derivatives
SG11201503051QA (en) Formulations of pyrimidinedione derivative compounds
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
SI2928896T1 (sl) Trdna oblika derivata dihidro-pirido-oksazina